Cargando…
Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
Immune checkpoint inhibitors are the mainstay of treatment for advanced melanoma, and their use is being increasingly implicated in the development of autoimmune endocrinopathies. We present a case of a 52-year-old man with metastatic melanoma on combination nivolumab and ipilumimab therapy who deve...
Autores principales: | Gunawan, Florence, George, Elizabeth, Roberts, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830856/ https://www.ncbi.nlm.nih.gov/pubmed/29511565 http://dx.doi.org/10.1530/EDM-17-0146 |
Ejemplares similares
-
Presentation of new onset type 1 diabetes with diabetic ketoacidosis and hyperosmolar hyperglycaemia after a single dose of nivolumab and ipilimumab
por: Stathi, Dimitra, et al.
Publicado: (2023) -
A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis
por: Yu, Christine, et al.
Publicado: (2015) -
Hyponatraemia secondary to nivolumab-induced primary adrenal failure
por: Trainer, Harris, et al.
Publicado: (2016) -
New-onset insulin-dependent diabetes due to nivolumab
por: Zaied, Ali A, et al.
Publicado: (2018) -
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
por: Tzoulis, Ploutarchos, et al.
Publicado: (2018)